SCHEMBL19722175

SCHEMBL19722175

C=C(CO)C(=O)OCCCC1CCC(c2ccc(C3CCC(C4CCC(CCCCC)CC4)CC3)cc2CC)CC1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 1/20 0.34
▸ MAPT P10636 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MEN1 O00255 2/20 0.31
▸ KMT2A Q03164 2/20 0.31
▸ S1PR1 P21453 5/20 0.31
▸ SGPL1 O95470 1/20 0.31
▸ NAAA Q02083 2/20 0.30
▸ HSD17B10 Q99714 1/20 0.30
▸ S1PR4 O95977 1/20 0.30
▸ S1PR5 Q9H228 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ CYP2C8 P10632 1/20 0.30
▸ S1PR3 Q99500 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19722417 0.93 CYP2C9 (0.34) CYP2C9MAPTALDH1A1LMNAMEN1
SCHEMBL19722247 0.92 CYP2C9 (0.31) CYP2C9MAPTALDH1A1LMNA
SCHEMBL19722409 0.91 CYP2C9 (0.34) CYP2C9MAPTALDH1A1LMNAMEN1
SCHEMBL19721885 0.90 CYP2C9 (0.33) CYP2C9MAPTALDH1A1LMNAS1PR1
SCHEMBL19722571 0.90 CYP2C9 (0.33) CYP2C9MAPTALDH1A1LMNAS1PR1
SCHEMBL19722115 0.90 CYP2C9 (0.33) CYP2C9MAPTALDH1A1LMNAS1PR1
SCHEMBL19722361 0.90 CYP2C9 (0.42) CYP2C9MAPTALDH1A1LMNAMEN1
SCHEMBL19755085 0.89 CYP2C9 (0.34) CYP2C9MAPTALDH1A1LMNAMEN1
SCHEMBL19722412 0.89 CYP2C9 (0.34) CYP2C9MAPTALDH1A1LMNAMEN1
SCHEMBL19722427 0.87 CYP2C9 (0.34) CYP2C9MAPTALDH1A1LMNAS1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210214615-A1 LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT JNC CORPORATION (JP) 2021-07-15 — — US disclosed
US-10392339-B2 Polymerizable polar compound, liquid crystal composition, and liquid crystal display element JNC CORPORATION (JP) 2019-08-27 — — US disclosed
WO-2018025974-A1 LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE JNC株式会社 2018-02-08 — — WO disclosed
US-20170369418-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC CORPORATION (JP) 2017-12-28 — — US disclosed
EP-3257839-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC Corporation (JP) 2017-12-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10392339-B2 Polymerizable polar compound, liquid crystal composition, and liquid crystal display element SP1, HVCN1, CXCR1 CYP2C9 4226/4885MAPT 1546/4885ALDH1A1 3882/4885
US-20170369418-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT SP1, SPIN1, SAV1 CYP2C9 4442/4885MAPT 1145/4885ALDH1A1 3267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback